CHECKMATE-004 Trial Results: 57% Of Patients Were Alive At 4 Years, Treatment Plan Was 2 Years, 23 Patients Completed Full Course

CHECKMATE-004 Trial Results: 57% Of Patients Were Alive At 4 Years, Treatment Plan Was 2 Years, 23 Patients Completed Full Course

Annual-Meeting

5 months
89 Views
Share
Want to watch this again later?
Sign in to add this video to a playlist. Login
0 0
Category:
Description:
Dr. Michael Atkins MD Of Georgetown University Discusses CHECKMATE-004 Trial Results: 57% Of Patients Were Alive At 4 Years, Treatment Plan Was 2 Years, 23 Patients Completed Full Course. BACKROUND: We previously reported a 3-year overall survival (OS) rate of 63% with NIVO+IPI concurrent therapy in the initial phase I dose-escalation study for the combination, conducted in patients (pts) with advanced melanoma. Here, we report OS after 5 years of overall study follow-up and assess survival rates after stopping treatment. METHODS: Adults with previously treated or untreated unresectable stage III or IV melanoma, and ECOG performance status of 0 or 1, received NIVO + IPI Q3W × 4 as mg/kg in one of the following cohorts: (1) NIVO 0.3 + IPI 3; (2) NIVO 1 + IPI 3; (2a) NIVO 3 + IPI 1; (3) NIVO 3 + IPI 3; (8) NIVO 1 + IPI 3. Cohorts 1-3 received maintenance with NIVO Q3W × 4, then NIVO + IPI Q12W × 8 at assigned doses; cohort 8 received NIVO Q2W for up to 96 weeks. Patients were followed for the primary endpoint of safety and the secondary endpoints of response and progression-free survival for up to 2.5 years, then for the survival exploratory endpoint for up to an additional 3 years, for a maximum study participation of 5.5 years. RESULTS: At a median follow-up of 43.1 months (range 0.9-76.7) in all cohorts (N = 94), the 4- and 4.5-year OS rates were both 57% (95% CI: 47, 67). The 4-year OS rates for pts with normal (n = 58) versus elevated LDH (n = 36) were 62% (48, 74) versus 49% (32, 65); for pts with wild-type (n = 66) and mutant (n = 24) BRAF tumors, 4-year OS rates were 54% (41, 65) and 61% (38, 77), respectively. Following the last dose of study drug (for any reason), overall post-treatment 1-, 2-, and 3-year OS rates were 74% (64, 82), 65% (55, 74), and 56% (46, 66), respectively; in pts who discontinued due to study drug toxicity (n = 32), post-treatment 1-, 2-, and 3-year OS rates were 84% (66, 93), 75% (55, 86), and 65% (45, 79), respectively, and in pts who discontinued for disease progression (n = 30), these were 52% (33, 68), 34% (18, 51), and 24% (11, 41), respectively. CONCLUSIONS: This updated analysis from study CA209-004 showed favorable survival outcomes with NIVO+IPI, regardless of BRAF or LDH status, and provided evidence of long-term survival following discontinuation of treatment in pts with advanced melanoma. Clinical trial information: NCT01024231
Up Next Autoplay
Annual meeting of the Society for Immunotherapy of Cancer (SITC) 2019 Polynoma Presenting Interim Phase III Evidence for Its Investigational Melanoma Vaccine, Seviprotimut-L
Annual meeting of the Society for Immunotherapy of Cancer (SITC) 2019 Polynoma Presenting Interim Phase III Evidence for Its Investigational Melanoma Vaccine, Seviprotimut-L
Category: Melanoma and Skin Cancer
18 Views
Cancer-News 5 days
Dual-function Virus Designed For Killing Tumor Cells and Helping Immune Cells
Dual-function Virus Designed For Killing Tumor Cells and Helping Immune Cells
Category: Melanoma and Skin Cancer
23 Views
Cancer-News 3 weeks
Will the CheckMate 204 data affect clinicians?
Will the CheckMate 204 data affect clinicians?
Category: Melanoma and Skin Cancer
11 Views
moasc 2 months
CheckMate 204 Study
CheckMate 204 Study
Category: Melanoma and Skin Cancer
10 Views
moasc 2 months
Clinicians could change the way they manage their patients
Clinicians could change the way they manage their patients
Category: Melanoma and Skin Cancer
3 Views
moasc 2 months
Fixing toxic therapy
Fixing toxic therapy
Category: Melanoma and Skin Cancer
6 Views
moasc 2 months
Alternate dosing for immunotherapy
Alternate dosing for immunotherapy
Category: Melanoma and Skin Cancer
2 Views
moasc 2 months
Is this data practice changing for clinicians?
Is this data practice changing for clinicians?
Category: Melanoma and Skin Cancer
1 Views
moasc 2 months
IMNC Data
IMNC Data
Category: Melanoma and Skin Cancer
4 Views
moasc 2 months
Follow up on The Long-Term Checkmake-004 in Metastatic Melanoma
Follow up on The Long-Term Checkmake-004 in Metastatic Melanoma
Category: Melanoma and Skin Cancer
19 Views
obr 4 months